Pfizer's top scientist Mikael Dolsten tells us the 2 factors that will determine if Omicron is a true threat and shares Pfizer's worst-case-scenario planBusiness Insider • 11/30/21
Pfizer CEO is 'very confident' the company's oral COVID-19 pill will be effective against the new variantBusiness Insider • 11/30/21
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell CarcinomaBusiness Wire • 11/30/21
FDA May Authorize Pfizer-BioNTech COVID-19 Booster Shots For Age 16-17 Next Week: WSJBenzinga • 11/30/21
Pfizer Reportedly Plans To Ask For Approval Of Covid Boosters For 16- And 17-Year-OldsForbes • 11/30/21
High Doses Of Dividend Growth Expected From Pfizer, Eli Lilly, Bristol Myers In DecemberSeeking Alpha • 11/29/21
5 Dividend Stocks Could Be Big Winners After the New COVID-19 Variant Shock24/7 Wall Street • 11/29/21
Week 48 MDA Breakout Stocks - December 2021: Short-Term Picks To Give You An EdgeSeeking Alpha • 11/28/21
Pfizer said an updated version of its COVID-19 vaccine will be 'ready in 100 days' if the new Omicron variant is resistant to its current vaccineBusiness Insider • 11/27/21